Immun-oncology Models
Antibody-Dependent Cellular Cytotoxicity (ADCC) Assay
The ADCC assay is a robust in vitro co-culture model used to validate potential therapeutic antibodies for their efficiency to mediate effector cell driven target cell cytotoxicity. Mimicking the natural immune response, the assay employs effector cells (PBMCs, NK cells, or Jurkat cells) to recognise and engage antibody bound target tumour cells.
Learn more
For a more in-depth look at our ADCC assays, click the button below to visit our webpage.
Available formats
Standard 96-well format.
Alternative format offerings available upon request.
Pilot assay development is available as a standalone service, or as a built in checkpoint for full studies.
FAQ
ADCC assays evaluate the ability of antibodies to induce immune-mediated cytotoxicity.
They combine target cells, effector cells, and antibodies. Fc receptor engagement triggers immune activation, leading to measurable target cell lysis.
They provide functional validation of antibody activity and help rank candidates based on their ability to recruit immune effectors.
Factors include effector-to-target ratio, antigen density, antibody affinity, and assay design.
Primary NK cells, PBMCs, and engineered cell lines are commonly used. Cellomatics selects systems based on study objectives.
They assess how Fc modifications influence receptor binding and immune activation, guiding antibody optimisation strategies.